Roche Holding AG (SWX:RO)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 240.79B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | n/a |
| EPS (ttm) | 11.74 |
| PE Ratio | 25.54 |
| Forward PE | 14.86 |
| Dividend | 9.70 (3.29%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 16,052 |
| Average Volume | 28,207 |
| Open | 294.00 |
| Previous Close | 295.20 |
| Day's Range | 290.80 - 294.60 |
| 52-Week Range | 244.00 - 333.60 |
| Beta | 0.18 |
| RSI | 52.65 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
FDA Approves Roche's Gazyva for Lupus Nephritis
FDA Approves Roche's Gazyva for Lupus Nephritis
My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
Rapt stock surged Monday after the biotech company said its experimental hives treatment topped Roche's Xolair in a 16-week study.
'Why the world is falling to bits?': Roche on his upcoming book
David Roche, president of Quantum Strategy discusses his new book, "Consequences: The Rise of a Fractured World Order" which talks about the global state of democracy and what entities are profiting o...
Roche's Gazyva Gets FDA Approval for Lupus Nephritis
The Food and Drug Administration approved Gazyva for the treatment of adults receiving standard therapy for a form of lupus that targets the kidneys.
Roche: FDA Approves Gazyva/Gazyvaro In Treatment Of Lupus Nephritis
(RTTNews) - Roche (RHHBY.PK) announced the FDA has approved Gazyva/Gazyvaro for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-...
Roche's Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for peopl...
Genentech's Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III IMvigor011 study evaluating Tecen...
FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patie...
FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva®...
Roche's Vamikibart Shows Promising Efficacy In Uveitic Macular Edema Across Phase III Trials
(RTTNews) - Roche has announced encouraging results from two Phase III clinical trials evaluating the investigational drug vamikibart (0.25 mg and 1 mg doses) for the treatment of uveitic macular edem...
Roche breast cancer drug improves survival of up to 62% in late-stage trial
Roche (RHHBF) unit Genentech posts encouraging late-stage trial data for its breast cancer drug giredestrant noting up to 62% survival benefit. Read more here.
Genentech's Giredestrant Combo Shows Strong Phase III Results In Advanced Breast Cancer Trial
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA Breast Cancer study. The data revealed that giredestrant in combination with everolimus ...
Genentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA Breast Cancer study. Data s...
Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Basel, 18 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus signi...
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1...
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety...
Roche (RHHBY) Secures Licensing Rights for Cancer Drug from Hansoh Pharma
Roche (RHHBY) Secures Licensing Rights for Cancer Drug from Hansoh Pharma
Roche licenses cancer candidate from China’s Hansoh Pharma
Roche Wins CHMP Support For Gazyva/Gazyvaro For Lupus Nephritis Treatment
(RTTNews) - Roche Holding AG (RHHBY.PK), Friday announced the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Gazyva/Gazyvaro in comb...
CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis
Basel, 17 October, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
The Zacks Analyst Blog Highlights NVIDIA, Roche, Lam Research, Tredegar and Kewaunee Scientific
NVIDIA, Roche, and Lam Research lead this week's top Zacks research picks, while Tredegar and Kewaunee Scientific highlight strong niche and microcap opportunities.
Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals
Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring growing international confidence in China’s life sciences...
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other...
Top Stock Reports for NVIDIA, Roche & Lam Research
NVIDIA, Roche, and Lam Research lead today's top Zacks reports, showcasing standout growth drivers and sector-specific strengths.